Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin Pariente
Edouard Louis

Showing results (281-290 of 364) with videos related to

Pageof 37
Sort By:
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 24, 2024
Rigorous Donor Selection for Fecal Microbiota Transplantation in Active Ulcerative Colitis: Key Lessons From a Randomized Controlled Trial Halted for FutilityClara Caenepeel, Sara Deleu, Jorge Francisco Vazquez Castellanos, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|January 9, 2025
Change in fatigue in patients with ulcerative colitis or Crohn's disease initiating biologic therapyEdouard Louis, Peter Bossuyt, Arnaud Colard, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 4, 2015
Subcutaneous Ustekinumab Provides Clinical Benefit for Two-Thirds of Patients With Crohn's Disease Refractory to Anti-Tumor Necrosis Factor AgentsPauline Wils, Yoram Bouhnik, Pierre Michetti, et al.
Journal of Crohn'S & Colitis|April 17, 2019
Long-term Clinical Effectiveness of Ustekinumab in Patients with Crohn's Disease Who Failed Biologic Therapies: A National Cohort StudyClaire Liefferinckx, Bram Verstockt, Ann Gils, et al.
Maedica|December 5, 2019
Environmental Factors in Romanian and Belgian Patients with Inflammatory Bowel Disease - a Retrospective Comparative StudyCarmen Monica Preda, Teodora Manuc, Doina Istratescu, et al.
Nature Communications|October 15, 2017
CCDC88B is required for pathogenesis of inflammatory bowel diseaseNassima Fodil, Neda Moradin, Vicki Leung, et al.
United European Gastroenterology Journal|November 18, 2021
Faster and less invasive tools to identify patients with ileal colonization by adherent-invasive E. coli in Crohn's diseaseAnthony Buisson, Emilie Vazeille, Mathurin Fumery, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 29, 2021
Steroid-Free Deep Remission at One Year Does Not Prevent Crohn's Disease Progression: Long-Term Data From the TAILORIX TrialDavid Laharie, Geert D'Haens, Maria Nachury, et al.
The New England Journal of Medicine|May 24, 2023
Upadacitinib Induction and Maintenance Therapy for Crohn's DiseaseEdward V Loftus, Julian Panés, Ana P Lacerda, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 16, 2024
Upadacitinib Achieves Clinical and Endoscopic Outcomes in Crohn's Disease Regardless of Prior Biologic ExposureLaurent Peyrin-Biroulet, Remo Panaccione, Edouard Louis, et al.
Pageof 37

Showing results (281-290 of 364) with videos related to

Sort By:
Pageof 37
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 24, 2024
Rigorous Donor Selection for Fecal Microbiota Transplantation in Active Ulcerative Colitis: Key Lessons From a Randomized Controlled Trial Halted for FutilityClara Caenepeel, Sara Deleu, Jorge Francisco Vazquez Castellanos, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|January 9, 2025
Change in fatigue in patients with ulcerative colitis or Crohn's disease initiating biologic therapyEdouard Louis, Peter Bossuyt, Arnaud Colard, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 4, 2015
Subcutaneous Ustekinumab Provides Clinical Benefit for Two-Thirds of Patients With Crohn's Disease Refractory to Anti-Tumor Necrosis Factor AgentsPauline Wils, Yoram Bouhnik, Pierre Michetti, et al.
Journal of Crohn'S & Colitis|April 17, 2019
Long-term Clinical Effectiveness of Ustekinumab in Patients with Crohn's Disease Who Failed Biologic Therapies: A National Cohort StudyClaire Liefferinckx, Bram Verstockt, Ann Gils, et al.
Maedica|December 5, 2019
Environmental Factors in Romanian and Belgian Patients with Inflammatory Bowel Disease - a Retrospective Comparative StudyCarmen Monica Preda, Teodora Manuc, Doina Istratescu, et al.
Nature Communications|October 15, 2017
CCDC88B is required for pathogenesis of inflammatory bowel diseaseNassima Fodil, Neda Moradin, Vicki Leung, et al.
United European Gastroenterology Journal|November 18, 2021
Faster and less invasive tools to identify patients with ileal colonization by adherent-invasive E. coli in Crohn's diseaseAnthony Buisson, Emilie Vazeille, Mathurin Fumery, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 29, 2021
Steroid-Free Deep Remission at One Year Does Not Prevent Crohn's Disease Progression: Long-Term Data From the TAILORIX TrialDavid Laharie, Geert D'Haens, Maria Nachury, et al.
The New England Journal of Medicine|May 24, 2023
Upadacitinib Induction and Maintenance Therapy for Crohn's DiseaseEdward V Loftus, Julian Panés, Ana P Lacerda, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 16, 2024
Upadacitinib Achieves Clinical and Endoscopic Outcomes in Crohn's Disease Regardless of Prior Biologic ExposureLaurent Peyrin-Biroulet, Remo Panaccione, Edouard Louis, et al.
Pageof 37